BioNTech price target raised to $133 from $132 at Morgan Stanley

Morgan Stanley analyst Terence Flynn raised the firm’s price target on BioNTech (BNTX) to $133 from $132 and keeps an Overweight rating on the shares. Year-to-date, large cap pharma and biotech companies have both underperformed given the macro environment, while multiple areas of policy uncertainty remain, including drug pricing dynamics, tariff and transfer pricing exposure, and FDA staffing changes, the analyst tells investors in a research note.